Form 10-Q Jazz Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jazz Pharmaceuticals (JAZZ) PT Lowered to $202 at BMO Capital
November 10, 2021 6:33 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $202.00 (from $205.00) while maintaining an Outperform rating.
The analyst commented, "3Q results beat with meaningfully lower opex driving significant EPS upside. Individual products were somewhat mixed, but we're seeing... More
